# The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes

> **NCT04219124** · PHASE4 · COMPLETED · sponsor: **University of Leicester** · enrollment: 9 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** IMP oral tablet
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04219124
- **Lead sponsor:** University of Leicester
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-20
- **Primary completion:** 2020-01-08
- **Final completion:** 2020-01-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04219124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04219124, "The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04219124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*